HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Magnesium Qualified Health Claims For Reducing Risk Of Hypertension Authorized In US

Executive Summary

CFSAN decides on Center for Magnesium Education and Research LLC's 2016 petition requesting FDA authorize a qualified health claim about relationship between magnesium and reduced risk of high blood pressure, or hypertension.

You may also be interested in...



QHC For Vitamin D, Omega-3 Helping Prevent Autoimmune Conditions Has VITAL Data Support

Trial for 5.3 years with more than 25,000 consumers 50 and older pointing to a link between vitamin D and imegta-3s and reducing autoimmune disease isn’t the first with results from VITAL. “It's a big one that we've been watching for a number of years. And it's exciting, some exciting outcomes,” says CRN scientific and regulatory affairs exec Andrea Wong.

US FDA Again Stops At Qualified Health Claim For Supplements: Cranberry Reduces UTI Risk

FDA intends to exercise enforcement discretion regarding QHCs about the association between reduced risk of recurrent UTI and use of supplements with at least 500 mg cranberry fruit powder and of cranberry juice beverages containing at least 27% cranberry juice.

Omega-3 Heart Health Claims Decision: FDA Out Of Step With Industry?

"The reality is that the FDA remains unwilling to rely upon a meta-analysis of only the highest quality studies in order to guide its final decision," GOED VP Harry Rice. "I think FDA has really lost sight of how the dietary supplement industry has changed," says attorney Charles Jolly.

Related Content

Topics

UsernamePublicRestriction

Register

RS152097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel